1503 related articles for article (PubMed ID: 18499745)
1. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
2. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
4. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
6. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
[TBL] [Abstract][Full Text] [Related]
7. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.
Sankaranarayanan S; Holahan MA; Colussi D; Crouthamel MC; Devanarayan V; Ellis J; Espeseth A; Gates AT; Graham SL; Gregro AR; Hazuda D; Hochman JH; Holloway K; Jin L; Kahana J; Lai MT; Lineberger J; McGaughey G; Moore KP; Nantermet P; Pietrak B; Price EA; Rajapakse H; Stauffer S; Steinbeiser MA; Seabrook G; Selnick HG; Shi XP; Stanton MG; Swestock J; Tugusheva K; Tyler KX; Vacca JP; Wong J; Wu G; Xu M; Cook JJ; Simon AJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):131-40. PubMed ID: 18854490
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
10. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters.
Lin HC; Hsieh HM; Chen YH; Hu ML
Neurotoxicology; 2009 Jul; 30(4):622-7. PubMed ID: 19635394
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
13. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
15. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
16. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
17. 2,2',4'-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice.
Zhu Z; Li C; Wang X; Yang Z; Chen J; Hu L; Jiang H; Shen X
J Neurochem; 2010 Jul; 114(2):374-85. PubMed ID: 20412384
[TBL] [Abstract][Full Text] [Related]
18. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
19. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing.
Rabe S; Reichwald J; Ammaturo D; de Strooper B; Saftig P; Neumann U; Staufenbiel M
J Neurochem; 2011 Oct; 119(1):231-9. PubMed ID: 21812781
[TBL] [Abstract][Full Text] [Related]
20. Measurement of cellular beta-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems.
Volbracht C; Penzkofer S; Mansson D; Christensen KV; Fog K; Schildknecht S; Leist M; Nielsen J
Anal Biochem; 2009 Apr; 387(2):208-20. PubMed ID: 19454261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
